Condition (MeSH)
Retinal Vasculitis
ClinicalTrials.gov lists 16 trials for Retinal Vasculitis or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
16 of the 16 trials are tagged with Retinal Vasculitis itself; the rest are tagged with a narrower condition beneath it.
When did Retinal Vasculitis trials start? (14)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2024 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2014 | 1 |
| 2010 | 2 |
| 2008 | 1 |
| 2007 | 1 |
Showing 10 of 14 earlier years.
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 16 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Retinal Vasculitis trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 3 | 1 |
| Phase 4 | 3 |
| Not applicable | 2 |
| Observational | 6 |
How many Retinal Vasculitis trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 11 |
| Terminated | 1 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Retinal Vasculitis trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Eye Institute (NEI) | 2 |
| Novartis Pharmaceuticals | 2 |
| Regeneron Pharmaceuticals | 2 |
Which drugs are being tested for Retinal Vasculitis? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| RITUXIMAB | 1 |
| Daclizumab | 1 |
| Brolucizumab | 1 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 2.0 aflibercept | 2 |
| Interferon-alpha2a | 1 |
| Etanercept, Methotrexate, Prednisolone | 1 |
| Cyclosporine 0.05% | 1 |
| methylorednisolone | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Retinal Vasculitis trials report? (5)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hypokalaemia | 1 | 1 |
| Pyelonephritis | 1 | 1 |
| Tibia fracture | 1 | 1 |
| Urinary tract infection | 1 | 1 |
| Uterine cancer | 1 | 1 |
Which publications cover Retinal Vasculitis? (21)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Defining Retinal Vasculitis. | American journal of ophthalmology | 2024 | Yes |
| Efficacy and safety of abatacept to treat active birdshot uveitis: a prospective open label interventional proof-of-concept trial. | The British journal of ophthalmology | 2024 | Yes |
| Complications of intravitreal injections: 2022. | Current opinion in ophthalmology | 2022 | Yes |
| Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. | Ophthalmology | 2021 | Yes |
| Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment. | Ophthalmology. Retina | 2021 | Yes |
Showing 5 of 21 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.